VS 01
Alternative Names: VS-01; VS-01-HACLatest Information Update: 28 May 2025
At a glance
- Originator Genfit; Versantis
- Class Drug withdrawal therapies; Tricarboxylic acids
- Mechanism of Action Ammonia scavengers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Hepatic encephalopathy; Liver failure
- Preclinical Hyperammonaemia; Inborn urea cycle disorders; Substance-related disorders
Most Recent Events
- 23 May 2025 Versantis AG plans a phase II trial for Hepatic encephalopathy and Liver Failure in June 2025 (NCT06987968)
- 24 Apr 2025 Genfit plans a first-in-human pediatric trial toward the end of 2026
- 24 Apr 2025 Genfit plans a pivotal juvenile toxicology study in Göttingen Minipigs as early as second half of 2025